Osseon Receives Patent Allowance for Novel Spinal VCF Treatment Devices

SANTA ROSA, Calif., July 14 /PRNewswire/ -- Osseon Therapeutics, Inc., a biomedical device company based in Santa Rosa, California, today received a notice of allowance for its spinal vertebral compression fracture (VCF) technology. The company which was started in 2006 has thirteen additional patent applications pending in the United States and throughout the world for related spinal therapies and devices. The lead inventor for this inaugural patent is Dr. Y. King Liu, one of three founders of Osseon.

The company has been marketing its FDA approved first generation "Osseoplasty™" systems since February, 2009. The Osseon devices received CE Mark in November 2009 and the company began marketing the product line in Europe in February of 2010. The proprietary Osseoplasty™ procedure has been performed in over 900 patients in the U.S. and Europe.

According to John Stalcup, Ph.D., CEO of Osseon, "This initial patent allowance for Osseon's spinal VCF technology is a major milestone for the company's intellectual property pursuits. We anticipate receiving a number of additional patents in the future on various aspects of the Osseoflex™ steerable and curvable needle and the novel methods for bone cement delivery, which enable a safe, effective, and minimally invasive approach for spine disease treatment."

About Osseon

Osseon Therapeutics, Inc. is focused on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease.  Headquartered in Santa Rosa, CA, the company's groundbreaking technology and delivery system provides comparable or better efficacy and safety than other commercial solutions while offering significant advantages in efficiency and cost. By improving the treatment of compression fractures within the lower portion of the thoracic and the entire lumbar vertebral spine, Osseon offers relief to those suffering from these maladies, as well as the physicians and medical facilities that treat them.  Its first-generation products have received both FDA clearance and the CE Mark for product distribution in the United States and European Union.  For more information, visit our web site at www.osseon.com.

SOURCE Osseon Therapeutics, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED